<DOC>
	<DOCNO>NCT00697879</DOCNO>
	<brief_summary>CHR-3996 one new class anti-cancer agent - histone deacetylase inhibitor ( HDACi ) - exhibit pleiotropic activity vitro vivo range human cancer cell . Regulation acetylation histone non-histone proteins histone deacetylase enzymes one key mechanism involve epigenetic control gene expression . HDACi demonstrate activity vitro cytotoxicity , vivo tumour xenograft study</brief_summary>
	<brief_title>Safety Study Histone Deacetylase Inhibitor , CHR-3996 , Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Signed , inform consent 2 . Histologically cytologically confirm malignant solid tumour refractory standard therapy standard therapy exist 3 . Recovered acute adverse effect prior therapy ( exclude alopecia grade 1 neuropathy ) 4 . Adequate bone marrow , hepatic renal function include follow 1 . Hb ≥ 9.0 g/dL , absolute neutrophil count ≥ 1.5 x 109/L , platelet ≥100 x 109/L 2 . Total bilirubin ≤ 1.5 x upper normal limit , exclude case elevate bilirubin attribute Gilberts Syndrome 3 . AST ( SGOT ) , ALT ( SGPT ) ≤ 2.5 x upper normal limit ( 5x UNL presence liver metastasis ) 4 . Creatinine ≤ 1.5 x upper normal limit 5 . Age ≥ 18 year 6 . Performance status ( PS ) ≤ 2 ( ECOG scale ) 7 . Estimated life expectancy great 3 month 8 . Female patient reproductive potential must negative serum pregnancy test within 7 day prior start trial . Both woman men must agree use medically acceptable method contraception throughout treatment period 3 month discontinuation treatment . Acceptable method contraception include IUD , oral contraceptive , subdermal implant double barrier ( condom contraceptive sponge ) EXCLUSION CRITERIA : 1 . Anticancer therapy include chemotherapy , radiotherapy , endocrine therapy , immunotherapy use investigational agent within 4 week prior trial entry ( long period depend defined characteristic agent use e.g . 6 week mitomycin nitrosourea , 3 month antibody ) . In patient progressive disease , continuation LHRH agonists prostate cancer , bisphosphonates bone disease corticosteroid permit provide dose change trial 2 . Patients prior allogeneic haematopoietic stem cell transplant 3 . Coexisting active infection serious concurrent illness 4 . Patients significant cardiovascular disease define : 1. history congestive heart failure require therapy 2. history angina pectoris require treatment myocardial infarction within 6 month prior trial entry 3. presence severe valvular heart disease 4. presence atrial ventricular arrhythmia require treatment 5 . LVEF normal range study centre 6 . Uncontrolled hypertension 7 . A history QTc abnormality mean QTc interval &gt; 450 msec screen 5 . Any medical condition investigator 's opinion render patient unsuitable study due unacceptable risk 6 . Psychiatric disorder alter mental status preclude understand informed consent process and/or completion necessary study 7 . Gastrointestinal disorder may interfere absorption study drug . 8 . Patients know brain tumour metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event 9 . More 6 prior chemotherapy regimens 10 . Patients require growth factor support ( erythropoietin , G ( M ) CSF , etc ) 11 . Patients require palliative radiotherapy within last 4 week prior study entry 12 . Uncontrolled hypercalcaemia ( &gt; CTCAE v3 grade I ) 13 . Abnormal plasma potassium magnesium level ( CTCAE v3 grade 3 great ) despite therapy 14 . Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>tumour</keyword>
	<keyword>Solid tumour</keyword>
	<keyword>histone deacetylase inhibitor</keyword>
	<keyword>dose escalation</keyword>
	<keyword>cancer</keyword>
</DOC>